First-line treatment of patients with advanced NSCLC with toripalimab plus chemotherapy resulted in improved progression-free survival and overall survival compared with chemotherapy alone. Read More ›

Sugemalimab plus chemotherapy resulted in statistically significant and clinically meaningful progression-free survival and overall survival improvement compared with placebo plus chemotherapy, regardless of tumor histology or PD-L1 expression level, in patients with newly diagnosed metastatic NSCLC. Read More ›

The 3-year extended follow-up of CheckMate 9LA demonstrated that first-line nivolumab plus ipilimumab in combination with limited chemotherapy resulted in long-term, durable clinical benefit compared with chemotherapy alone in patients with metastatic NSCLC, regardless of PD-L1 mutation status. Read More ›

The PIONeeR trial identified 37 biomarkers that could predict resistance to anti–PD-1/PD-L1 therapy before treatment initiation. Read More ›

The safety profile of durvalumab ± tremelimumab plus chemotherapy was manageable, but with more immune-related adverse events observed with durvalumab and tremelimumab. Read More ›

Camrelizumab plus albumin paclitaxel and apatinib resulted in promising antitumor activity with an acceptable safety profile for first-line treatment of advanced NSCLC. Read More ›

MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor, showed promising antitumor activity and durable clinical benefit and was tolerated at doses 1500 mg. Read More ›

Analysis of the changes in blood circulating soluble proteins resulted in identifying potential response biomarkers to immune checkpoint inhibitors in patients with squamous-cell lung cancer. Read More ›

Nivolumab plus ipilimumab demonstrates deep and sustained confirmed responses for patients with metastatic uveal melanoma. Read More ›